- Immunic to Participate in Investor and Scientific Conferences in May
- Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
- Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
- Immunic to Host MS R&D Day and Participate in Investor Conferences in April
- Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
- Immunic to Participate in Investor and Scientific Conferences in March
- Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
- Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
- Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
More ▼
Key statistics
On Monday, Immunic Inc (IMUX:NSQ) closed at 1.34, 41.78% above the 52 week low of 0.9451 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.37 |
---|---|
High | 1.38 |
Low | 1.33 |
Bid | 1.30 |
Offer | 1.37 |
Previous close | 1.34 |
Average volume | 174.48k |
---|---|
Shares outstanding | 90.08m |
Free float | 83.12m |
P/E (TTM) | -- |
Market cap | 120.71m USD |
EPS (TTM) | -2.11 USD |
Data delayed at least 15 minutes, as of May 06 2024 21:00 BST.
More ▼